NCT02440204

Brief Summary

Intubation is a procedure that requires well relaxed muscles while general anesthesia is performed. In order to get adequate muscle relaxation, remifentanil, sevoflurane or both agents in combination have been reported as they can provide adequate conditions for laryngoscopy and tracheal intubation without using muscle relaxants. However, there were no previous studies to find the effective dose of sevoflurane in combination with different bolus doses of remifentanil to obtain adequate endotracheal intubation conditions without using muscle relaxants. The aim of this study is to investigate the change in the minimum sevoflurane alveolar concentration which produces an adequate endotracheal intubation condition when sevoflurane is combined with different bolus doses of remifentanil used in clinical practice.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P25-P50 for not_applicable postoperative-pain

Timeline
Completed

Started May 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2015

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

May 5, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 12, 2015

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

January 17, 2019

Completed
Last Updated

January 17, 2019

Status Verified

July 1, 2018

Enrollment Period

11 months

First QC Date

May 5, 2015

Results QC Date

July 20, 2017

Last Update Submit

July 19, 2018

Conditions

Keywords

sevofluraneremifentanilintubation without using muscle relaxants

Outcome Measures

Primary Outcomes (1)

  • EC50 for Successful Intubation in Each Groups

    Sevoflurane concentration used to perform intubation (For ED50 finding)

    During the induction of anesthesia

Secondary Outcomes (1)

  • EC95 for Successful Intubation

    During the induction of anesthesia

Study Arms (3)

Remifentanil 1.0 mcg/kg

ACTIVE COMPARATOR

After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.

Procedure: IntubationDrug: RemifentanilDrug: Sevoflurane

Remifentanil 1.5 mcg/kg

ACTIVE COMPARATOR

After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.

Procedure: IntubationDrug: RemifentanilDrug: Sevoflurane

Remifentanil 2.0 mcg/kg

ACTIVE COMPARATOR

After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.

Procedure: IntubationDrug: RemifentanilDrug: Sevoflurane

Interventions

IntubationPROCEDURE

After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.

Remifentanil 1.0 mcg/kgRemifentanil 1.5 mcg/kgRemifentanil 2.0 mcg/kg

After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.

Also known as: Ultiva
Remifentanil 1.0 mcg/kgRemifentanil 1.5 mcg/kgRemifentanil 2.0 mcg/kg

The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.

Also known as: Sevoran
Remifentanil 1.0 mcg/kgRemifentanil 1.5 mcg/kgRemifentanil 2.0 mcg/kg

Eligibility Criteria

Age19 Years - 30 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • American Society of Anesthesiologists physical status I or II who were scheduled to undergo elective otolaryngological surgery

You may not qualify if:

  • history of reactive airway disease
  • smoking hx.
  • a predictive signs of difficult intubation
  • body mass index ≥ 30 kg•m-2 or ≤ 15 kg•m-2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Armed Forces Capital Hospital, Republic of Korea

Seongnam-si, Kyung-ki Do, South Korea

Location

Related Publications (3)

  • Cros AM, Lopez C, Kandel T, Sztark F. Determination of sevoflurane alveolar concentration for tracheal intubation with remifentanil, and no muscle relaxant. Anaesthesia. 2000 Oct;55(10):965-9. doi: 10.1046/j.1365-2044.2000.01538.x.

    PMID: 11012491BACKGROUND
  • Min SK, Kwak YL, Park SY, Kim JS, Kim JY. The optimal dose of remifentanil for intubation during sevoflurane induction without neuromuscular blockade in children. Anaesthesia. 2007 May;62(5):446-50. doi: 10.1111/j.1365-2044.2007.05037.x.

    PMID: 17448054BACKGROUND
  • Dixon WJ. Staircase bioassay: the up-and-down method. Neurosci Biobehav Rev. 1991 Spring;15(1):47-50. doi: 10.1016/s0149-7634(05)80090-9.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

IntubationRemifentanilSevoflurane

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

TherapeuticsInvestigative TechniquesPropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMethyl EthersEthersHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbons

Results Point of Contact

Title
Dr. Jae Chul Koh
Organization
Severance

Study Officials

  • Eui-Kyoung Goo, MD

    Armed forces capital hospital

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Fellow, Department of anesthesiology and pain medicine

Study Record Dates

First Submitted

May 5, 2015

First Posted

May 12, 2015

Study Start

May 1, 2015

Primary Completion

April 1, 2016

Study Completion

April 1, 2016

Last Updated

January 17, 2019

Results First Posted

January 17, 2019

Record last verified: 2018-07

Locations